Christopher Bunker, Ph.D., M.B.A.
About Christopher Bunker, Ph.D., M.B.A.
Christopher Bunker, Ph.D., M.B.A., serves as the Vice President of Biopharma Business Development at Alamar Biosciences, Inc. He has extensive experience in business development within the biopharma sector, having held leadership roles at various organizations including Cell Signaling Technology and Advanced Cell Diagnostics.
Current Role at Alamar Biosciences
Christopher Bunker, Ph.D., M.B.A., serves as the Vice President of Biopharma Business Development at Alamar Biosciences, Inc. He has held this position since 2022, contributing to the company's focus on innovative biopharmaceutical solutions. His role involves strategic development and partnership initiatives aimed at advancing the company's biopharma portfolio within the San Francisco Bay Area.
Previous Experience in Business Development
Prior to his current role, Bunker accumulated extensive experience in business development within the biopharma sector. He worked at Advanced Cell Diagnostics as Vice President of Business Development from 2012 to 2021, and earlier as Senior Director of Business Development from 2010 to 2011. He also held the position of Director of Business Development at Cell Signaling Technology from 2003 to 2010. His brief tenure as Senior Director at Triplebar in 2021 further highlights his diverse background in the industry.
Educational Background and Expertise
Bunker holds a Doctor of Philosophy (Ph.D.) in Biological Chemistry & Molecular Pharmacology from Harvard University, where he studied from 1988 to 1995. He also earned a Master of Business Administration (M.B.A.) from the Questrom School of Business at Boston University between 2008 and 2010. Additionally, he completed a Leukemia Society Postdoctoral Fellowship at the University of California, San Francisco, focusing on Molecular Genetics. His foundational education includes a Bachelor of Science (B.Sc.) in Biochemistry from McGill University.
Research and Development Contributions
Christopher Bunker has been involved in significant research and development projects, including the creation of NULISA proteomics, a fully automated liquid biopsy platform. His expertise extends to high affinity agonist and antagonist Attobodies for partnered therapeutics. He focuses on companion diagnostics aimed at the early detection of cancer and other diseases, contributing to advancements in precision medicine.
Presentations and Industry Engagement
Bunker has actively participated in various industry summits, presenting on topics such as ultra-sensitive and multiplex immunoassay platforms for fluid biomarkers in central nervous system diseases. He has also presented at the Neuroimmunology and Drug Development Summit, as well as the Alzheimer's and Parkinson's Drug Development Summit, showcasing his expertise and contributions to the field.